The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global […]
Funding to Accelerate Commercialization of the Optimizer Smart System for Heart Failure MOUNT LAUREL, N.J.–(BUSINESS WIRE)–Impulse Dynamics, developer of Optimizer® Smart System for delivering CCM™ therapy, announced the completion of an $80.25 million Series D financing with new investors. The proceeds will be used primarily to facilitate U.S. commercialization of the […]
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and nine months ended September 30, 2019. Recent Operational Highlights Launched the new Pharos, Optimized dermatology laser (July 2019), which […]
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30. The notice for the year-end change required under National Instrument 51-102 […]
December 2, 2019 Leading health system leverages Philips diagnostic imaging and patient monitoring solutions to deliver on Quadruple Aim: better outcomes, increased efficiency, and improved patient and staff experience Andover, U.S. and Mullica Hill, U.S. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Inspira Health (Inspira), today […]
CALGARY, Alberta, Nov. 29, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces the appointment of Mr. Thomas Smeenk, BA, to […]
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer, stated, “On behalf of Novoheart, I would […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the appointment of Mr Alexandre Eleonore as Director of Manufacturing. Alexandre Eleonore is a […]
WINNIPEG, Nov. 26, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019. Quarter Ended September 30, 2019 Highlights: Recorded net revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $5.3 million during the quarter ended September 30, 2019 compared to $7.0 million for the […]
Continued Increase in Revenues and Strong Balance Sheet MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “The Company’s financial results for […]
